{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:31:46Z","timestamp":1726014706717},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma (MM) arises in plasma cells, a type of white blood cell. The cancerous plasma cells produce monoclonal immunoglobulins in the bone marrow. The extent of proliferation in the malignant state can manifest in many complications including osteopenia, osteolytic lesions, pathologic fractures, hypercalcemia, anemia, and kidney dysfunction. As is the case with the treatment of other malignancies, the research relating to the management of MM is dynamic and evolving. In this review, we aim to succinctly summarize and categorize the major treatment options of MM, including both new treatments and also older treatments that are now less frequently utilized, with a specific focus on the cardiotoxicity of these agents.<\/jats:p>","DOI":"10.1097\/crd.0000000000000787","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:23:29Z","timestamp":1725981809000},"update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Complications of Multiple Myeloma Treatments"],"prefix":"10.1097","author":[{"given":"Aatif","family":"Khurshid","sequence":"first","affiliation":[{"name":"Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"R1-20240910","doi-asserted-by":"crossref","first-page":"e052759","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care.","volume":"11","author":"Seesaghur","year":"2021","journal-title":"BMJ Open"},{"key":"R2-20240910","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R3-20240910","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma.","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20240910","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.2174\/1381612825666190111101459","article-title":"Cancer therapeutics-related cardiovascular complications. mechanisms, diagnosis and treatment.","volume":"24","author":"Oikonomou","year":"2018","journal-title":"Curr Pharm Des"},{"key":"R5-20240910","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.3390\/ijms19113572","article-title":"Effects of cardiovascular risk factors on cardiac STAT3.","volume":"19","author":"Pipicz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R6-20240910","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2991\/chi.k.210201.001","article-title":"How to simplify the evaluation of newly introduced chemotherapeutic interventions in myeloma.","volume":"3","author":"Morris","year":"2021","journal-title":"Clin Hematol Int"},{"key":"R7-20240910","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-20240910","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-006-0078-0","article-title":"Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.","volume":"23","author":"Korkmaz","year":"2007","journal-title":"Cell Biol Toxicol"},{"key":"R9-20240910","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision.","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"R10-20240910","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.1200\/jco.2014.32.15_suppl.8586","article-title":"Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed\/refractory multiple myeloma.","volume":"32","author":"Monge","year":"2014","journal-title":"J Clin Oncol"},{"key":"R11-20240910","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1586\/14737140.7.7.945","article-title":"Melphalan and its role in the management of patients with multiple myeloma.","volume":"7","author":"Falco","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"R13-20240910","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors.","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin Cardiol"},{"key":"R14-20240910","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.bbmt.2010.12.157","article-title":"Cardiomyopathy following high dose melphalan conditioning prior to autologous peripheral blood stem cell transplantation for multiple myeloma and primary amyloidosis.","volume":"17","author":"Bleeker","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-20240910","doi-asserted-by":"crossref","first-page":"e0773","DOI":"10.1097\/CAD.0000000000000773","article-title":"PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.","volume":"30","author":"Fu","year":"2019","journal-title":"Anticancer Drugs"},{"key":"R16-20240910","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress.","volume":"17","author":"Imam","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"R17-20240910","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474086.2017.1284584","article-title":"Safety issues and management of toxicities associated with new treatments for multiple myeloma.","volume":"10","author":"Brioli","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R18-20240910","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis.","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"R19-20240910","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"R20-20240910","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"R21-20240910","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"R22-20240910","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"R23-20240910","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bcp.15499","article-title":"Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study.","volume":"89","author":"Al-Yafeai","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20240910","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives.","volume":"96","author":"Ito","year":"2020","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R25-20240910","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review.","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"R26-20240910","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during therapy for multiple myeloma with thalidomide.","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol"},{"key":"R27-20240910","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials.","volume":"40","author":"Das","year":"2022","journal-title":"Haematol Oncol"},{"key":"R28-20240910","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies.","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"R29-20240910","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"R30-20240910","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"R31-20240910","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"R32-20240910","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"R33-20240910","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","article-title":"Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.","volume":"16","author":"Lonial","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"R34-20240910","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"R35-20240910","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"R36-20240910","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T Cell therapy: a versatile living drug.","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R37-20240910","doi-asserted-by":"crossref","first-page":"113","DOI":"10.36401\/JIPO-20-10","article-title":"Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias.","volume":"3","author":"Simbaqueba","year":"2020","journal-title":"J Immunother Precis Oncol"},{"key":"R38-20240910","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management: Systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R39-20240910","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma.","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:23:50Z","timestamp":1725981830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000787","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}